Nrf2 activation in osteoblasts suppresses osteoclastogenesis via inhibiting IL-6 expression

Tsuyoshi Narimiya; Hiroyuki Kanzaki; Yuki Yamaguchi; Satoshi Wada; Yuta Katsumata; Ken Tanaka; Hiroshi Tomonari

doi:10.1016/j.bonr.2019.100228

Nrf2 activation in osteoblasts suppresses osteoclastogenesis via inhibiting IL-6 expression

Bone Rep. 2019 Nov 1:11:100228. doi: 10.1016/j.bonr.2019.100228. eCollection 2019 Dec.

Authors

Tsuyoshi Narimiya¹, Hiroyuki Kanzaki¹, Yuki Yamaguchi¹, Satoshi Wada¹, Yuta Katsumata¹, Ken Tanaka¹, Hiroshi Tomonari¹

Affiliation

¹ Department of Orthodontics, School of Dental Medicine, Tsurumi University, 2-1-3 Tsurumi, Tsurumi-ku, Yokohama, Kanagawa pref., 230-8501, Japan.

Abstract

Bone destructive diseases such as periodontitis and rheumatoid arthritis are caused by excessive activation of osteoclasts. Osteoclastogenesis is regulated by Receptor activator of nuclear factor kappa-β ligand (RANKL) produced by osteoclastogenesis supporting cells such as osteoblast and osteocyte. Previously, we reported that NF-E2-related factor-2 (Nrf2) activation in osteoclast precursors inhibited osteoclastogenesis and bone destruction via induction of anti-oxidation and thereby attenuated intracellular ROS signaling. However, it still remains unknown whether Nrf2 activation in cells other than osteoclasts give any negative influence on supporting property for osteoclastogenesis. Here we discovered that Nrf2 activation in osteoblasts suppresses indirectly osteoclastogenesis via inhibiting the expression of interleukin-6 (IL-6) which promotes osteoclastogenesis. In this study, 5-aminolevulinic acid hydrochloride (ALA) and sodium ferrous citrate (SFC) was used as the Nrf2 activator. in vitro experiments, using osteoblast cell line, MC3T3-E1, revealed that the expression of IL-6 was increased by LPS stimulation, but decreased after ALA/SFC treatment in mRNA and protein levels. Furthermore, RANKL expression was augmented by LPS, which was blocked by ALA/SFC treatment. Neutralizing antibody against IL-6 confirmed that LPS-mediated RANKL augmentation was dependent on IL-6 induction. in vivo experiments with LPS-mediated bone destruction in mice, confirmed that augmented IL-6 expression in osteoblasts by immunochemical analysis. ALA/SFC treatment attenuated LPS-mediated IL-6 upregulation. These results suggest that Nrf2 activation in osteoblasts suppress IL-6 and inflammatory bone destruction. The Nrf2 activator acts not only on osteoclasts but also on osteoblasts, in other word, Nrf2 activation indirectly suppresses osteoclastogenesis. In conclusion, the Nrf2 activator exhibits dual inhibitory effects via direct action on osteoclast and indirect action on osteoclast supporting cells.

Keywords: ALA/SFC; IL-6; Nrf2; Osteoblast; Osteoclast; Osteoclastogenesis.